Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

Partner | Cancer Centers | <b>Siteman</b>

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Brian A. Van Tine, MD, PhD, associate professor, Department of Medicine; director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis; and medical oncologist, Siteman Cancer Center, discusses outcomes with catequentinib (Anlotinib) in the treatment of patients with synovial sarcoma. 

The randomized phase 3 APROMISS trial (NCT03016819) examined catequentinib vs dacarbazine in patients with advanced or metastatic synovial sarcoma. Because synovial sarcoma only represents approximately 10% of soft tissue sarcoma cases, and the study only enrolled those with advanced or metastatic disease who had undergone prior treatment with an anthracycline-based chemotherapy, the study population was very limited, according to Van Tine.

Results showed a progression-free survival benefit in patients treated with catequentinib compared with those who received dacarbazine. More importantly, it was found that prior treatment with pazopanib (Votrient) did not impact outcomes, Van Tine notes. This suggests that patients with synovial sarcoma may be able to receive treatment with multiple TKIs, Van Tine concludes.